Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Income from Continuing Operations (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Income from Continuing Operations over the past 16 years, most recently at 1147000.0 for Q2 2025.

  • For Q2 2025, Income from Continuing Operations rose 83.81% year-over-year to 1147000.0; the TTM value through May 2025 reached 38717000.0, down 514.93%, while the annual FY2025 figure was 38717000.0, 514.93% down from the prior year.
  • Income from Continuing Operations for Q2 2025 was 1147000.0 at Lifecore Biomedical, Inc. \De\, up from 14769000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 14785000.0 in Q1 2024 and troughed at 36998000.0 in Q2 2023.
  • A 5-year average of 7708444.44 and a median of 8837000.0 in 2021 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 1001.54% in 2021 and later surged 254.79% in 2023.
  • Year by year, Income from Continuing Operations stood at 7547000.0 in 2021, then crashed by 221.92% to 9201000.0 in 2022, then surged by 254.79% to 14242000.0 in 2023, then crashed by 146.14% to 6571000.0 in 2024, then surged by 82.54% to 1147000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for LFCR at 1147000.0 in Q2 2025, 14769000.0 in Q1 2025, and 6571000.0 in Q4 2024.